MAGEA4 and synovial sarcoma: The SPEARHEAD-1 clinical trial of afamitresgene autoleucel (afami-cel), an engineered TCR-T cell therapy against MAGE-A4, demonstrated a 39% response rate in heavily pre-treated patients with synovial sarcomas [38], leading to the first FDA approval of an engineered T-cell therapy in solid tumors.